| Unternehmen / Aktien | News 24 h | News 7 T | Kurs | ||
|---|---|---|---|---|---|
| REGENERON PHARMACEUTICALS | 12 | 22 | +2,27 % | ||
| MEDPACE | 7 | - | -22,87 % | ||
| BIONTECH | 6 | 13 | -2,58 % | ||
| ALTIMMUNE | 6 | - | -17,23 % | ||
| CORVUS PHARMACEUTICALS | 3 | - | -12,69 % | ||
| BIOMARIN PHARMACEUTICAL | 2 | 12 | +0,45 % | ||
| ZAI LAB LTD ADR | 2 | 6 | -4,62 % | ||
| TECTONIC THERAPEUTIC | 2 | 1 | +0,60 % | ||
| VANDA PHARMACEUTICALS | 2 | - | -3,86 % | ||
| BLACK DIAMOND THERAPEUTICS | 2 | - | -7,59 % |
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 22:46 | FDA approves Regeneron's hearing loss gene therapy | 3 | BioPharma Dive | ||
| 22:10 | Regeneron ushers in new genetic medicine era with groundbreaking gene therapy approval | 2 | FiercePharma | ||
| 22:10 | Regeneron: Kostenlose Gentherapie und globale Preisanpassung für US-Markt | 2 | Investing.com Deutsch | ||
| 22:06 | Regeneron to offer gene therapy free, align U.S. drug prices globally | 4 | Investing.com | ||
| 22:06 | Tectonic Therapeutic Appoints Jessica Chutter to Board of Directors | 1 | GlobeNewswire (USA) | ||
| 22:06 | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals to Report First Quarter 2026 Financial Results on April 28, 2026 | 1 | GlobeNewswire (USA) | ||
| 22:06 | Dyne Therapeutics, Inc.: Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| 22:06 | Trevi Therapeutics, Inc.: Trevi Therapeutics to Participate in Upcoming May Events | 1 | GlobeNewswire (USA) | ||
| 21:48 | Regeneron Pharmaceuticals, Inc.: Regeneron Announces Agreement with U.S. Government to Help Lower Drug Costs for American Patients and Will Provide Innovative New Gene Therapy for Free in the U.S. | 2 | GlobeNewswire (USA) | ||
| 21:31 | Tectonic Therapeutic, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 21:30 | Corvus Pharmaceuticals, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 21:21 | BIOMARIN PHARMACEUTICAL INC - 8-K, Current Report | - | SEC Filings | ||
| 21:10 | Regeneron to unveil latest 'most favored nation' drug pricing deal with White House | 2 | FiercePharma | ||
| 20:30 | Medpace Flags Rising Cancellations, Near-Term Growth Uncertain | 3 | Benzinga.com | ||
| 20:10 | With Dupixent driving growth, Sanofi touts 'vigorous defense' to extend US exclusivity | 3 | FiercePharma | ||
| 19:30 | Regeneron wins FDA approval for hearing loss therapy | 4 | Seeking Alpha | ||
| 19:26 | BNP Paribas Downgrades Sanofi (SNY) with 'Unlikely Near-Term Rerating' | 11 | Insider Monkey | ||
| 18:42 | Regeneron Pharmaceuticals, Inc.: Otarmeni (lunsotogene parvec-cwha) Approved by FDA as First and Only Gene Therapy for Genetic Hearing Loss; Regeneron to Provide Otarmeni for Free in the U.S. | 2 | GlobeNewswire (USA) | ||
| 18:34 | SNY & REGN's Dupixent Wins FDA Nod for Pediatric Use in Urticaria | 2 | Zacks | ||
| 18:34 | Is Altimmune a Buy Before Phase III MASH Starts in 2026? | 4 | Zacks |